Grail Inc ( (GRAL) ) has released its Q3 earnings. Here is a breakdown of the information Grail Inc presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Grail Inc. is a healthcare company focused on early cancer detection using advanced sequencing and machine learning technologies, aiming to alleviate the global cancer burden. In its third-quarter 2025 earnings report, Grail Inc. announced a significant increase in revenue and test sales, with U.S. Galleri revenue growing by 28% year-over-year to $32.6 million and Galleri test sales increasing by 39% to over 45,000 tests. The company also highlighted its strong cash position of over $850 million, bolstered by a recent private placement.
Key financial metrics from the report include a total revenue increase of 26% year-over-year to $36.2 million and a net loss improvement of 29% to $89.0 million. The company reported an adjusted gross profit of $20.0 million, a 69% increase, and an adjusted EBITDA improvement of 34% to $(71.7) million. Strategic advancements include a collaboration with Samsung to expand into Asian markets and the introduction of Galleri in Canada.
Grail’s recent studies, PATHFINDER 2 and SYMPLIFY, have shown promising results in multi-cancer early detection, with Galleri detecting significantly more cancers compared to standard screenings. The company is also working with Medcan and Manulife Canada to increase access to its Galleri test.
Looking ahead, Grail Inc. anticipates submitting its Galleri test for FDA approval in the first quarter of 2026, while continuing to expand its market presence and enhance its financial performance.